| Benjamin D Suhr, MD | |
|
1973 Sloan Pl, #225, Maplewood, MN 55117-2084 | |
| (651) 224-1347 | |
| (651) 776-0932 |
| Full Name | Benjamin D Suhr |
|---|---|
| Gender | Male |
| Speciality | Surgery |
| Location | 1973 Sloan Pl, Maplewood, Minnesota |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1720029630 | NPI | - | NPPES |
| 34075700 | Medicaid | WI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208600000X | Surgery | 39524 (Minnesota) | Primary |
| Entity Name | Minnesota Surgical Associates Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1841336054 PECOS PAC ID: 2062514821 Enrollment ID: O20070226000065 |
News Archive
Depomed, Inc. announced today it has received guidance from the FDA in formal meeting minutes from a meeting held in December regarding SeradaTM, the company's extended release gabapentin product candidate for the treatment of menopausal hot flashes. Based on guidance reflected in the meeting minutes, Depomed plans to conduct a single additional pivotal Phase 3 trial evaluating Serada for the treatment of menopausal hot flashes.
IOF WCO-ECCEO10 will be the largest global scientific meeting devoted exclusively to osteoporosis and osteoarthritis in 2010. We look forward to welcoming you in Florence next spring!
Washington State University researchers have discovered a genetic variation that predicts how well people perform certain mental tasks when they are sleep deprived.
Lorus Therapeutics Inc. today announced that the Food and Drug Administration completed its review and cleared the company's Investigational New Drug (IND) application of LOR-253 for the treatment of hematologic malignancies including acute myeloid leukemia (AML), high-risk myelodysplastic syndromes (MDS), lymphomas and multiple myeloma.
Titan Pharmaceuticals, Inc. today announced that the National Institutes of Health has awarded the company a grant under the Small Business Innovation Research program supporting the development of a long-term, non-fluctuating dopamine agonist treatment for Parkinson's disease. The first year award in the amount of $300,000 will be available to Titan starting August 1, 2010, and an additional $195,000 for the second year starting August 1, 2011 has been recommended subject to availability of funds and satisfactory progress of the project. The grant will be administered by the National Institute of Neurological Disorders and Stroke.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Benjamin D Suhr, MD 1973 Sloan Pl, #225, Maplewood, MN 55117-2084 Ph: (651) 224-1347 | Benjamin D Suhr, MD 1973 Sloan Pl, #225, Maplewood, MN 55117-2084 Ph: (651) 224-1347 |
News Archive
Depomed, Inc. announced today it has received guidance from the FDA in formal meeting minutes from a meeting held in December regarding SeradaTM, the company's extended release gabapentin product candidate for the treatment of menopausal hot flashes. Based on guidance reflected in the meeting minutes, Depomed plans to conduct a single additional pivotal Phase 3 trial evaluating Serada for the treatment of menopausal hot flashes.
IOF WCO-ECCEO10 will be the largest global scientific meeting devoted exclusively to osteoporosis and osteoarthritis in 2010. We look forward to welcoming you in Florence next spring!
Washington State University researchers have discovered a genetic variation that predicts how well people perform certain mental tasks when they are sleep deprived.
Lorus Therapeutics Inc. today announced that the Food and Drug Administration completed its review and cleared the company's Investigational New Drug (IND) application of LOR-253 for the treatment of hematologic malignancies including acute myeloid leukemia (AML), high-risk myelodysplastic syndromes (MDS), lymphomas and multiple myeloma.
Titan Pharmaceuticals, Inc. today announced that the National Institutes of Health has awarded the company a grant under the Small Business Innovation Research program supporting the development of a long-term, non-fluctuating dopamine agonist treatment for Parkinson's disease. The first year award in the amount of $300,000 will be available to Titan starting August 1, 2010, and an additional $195,000 for the second year starting August 1, 2011 has been recommended subject to availability of funds and satisfactory progress of the project. The grant will be administered by the National Institute of Neurological Disorders and Stroke.
› Verified 1 days ago
Dr. Peter B Wilton, MD Surgery Medicare: Medicare Enrolled Practice Location: 1655 Beam Ave Ste 302, Maplewood, MN 55109 Phone: 651-227-6351 | |
John G Shearen, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 1997 Sloan Pl, Suite 17, Maplewood, MN 55117 Phone: 715-531-6800 Fax: 715-531-6801 | |
Roy Ea Hope, M.D. Surgery Medicare: Not Enrolled in Medicare Practice Location: 1973 Sloan Pl, #225, Maplewood, MN 55117 Phone: 651-224-1347 Fax: 651-855-0126 | |
Geoffrey S. Fasen, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 2945 Hazelwood St Ste 100, Maplewood, MN 55109 Phone: 651-227-6351 Fax: 651-227-1134 | |
Keith Matthew Wirth, Surgery Medicare: Medicare Enrolled Practice Location: 2945 Hazelwood St Ste 200, Maplewood, MN 55109 Phone: 612-232-7800 | |
Ryan Christopher Knoper, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 2945 Hazelwood St Ste 100, Maplewood, MN 55109 Phone: 651-227-6351 | |
Dr. James M. Mcgreevy, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 1655 Beam Ave, Suite 302, Maplewood, MN 55109 Phone: 651-227-6351 Fax: 651-227-1134 |